Clinical trials: Semaglutide
Diabetes, Healthy
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
This trial is conducted in Europe. The aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.
- Trial name
- NCT02557620
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study.
- Trial name
- NCT05202353
- Testing
- BI 456906, Semaglutide
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes, Healthy
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
- Trial name
- NCT03010475
- Testing
- Furosemide, Rosuvastatin, SNAC
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alcohol Use Disorder
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans.
- Trial name
- CRAVE (NCT07218354)
- Testing
- Semaglutide
- Where
- 19 sites in United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine.
- Trial name
- NCT05046873
- Testing
- Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Diabetes, Healthy
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on pharmacokinetics (the exposure of the trial drug in the body) of metformin and digoxin in healthy subjects.
- Trial name
- NCT02249910
- Testing
- semaglutide, metformin, digoxin
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
This study will test how the active substances semaglutide and dapagliflozin act in the body (in terms of their levels in the blood), when they are taken in the form of a combination preparation (a tablet with a fixed dose…
- Trial name
- NCT05429593
- Testing
- Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin
- Where
- 2 sites in Germany
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
In this study a known investigational medicinal product called semaglutide will be tested in four different tablet versions. In addition to semaglutide, the different tablet versions C, D, E and F contain different helping agents…
- Trial name
- NCT04524832
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. One is the current formulation and the other one is a new formulation of semaglutide.
- Trial name
- NCT04097600
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of subcutaneous injections of three different strengths of semaglutide and the absolute…
- Trial name
- NCT02231684
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Adolescent
Young Adults With Early-onset Obesity Treated With Semaglutide
Introduction: The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions.
- Trial name
- RESETTLE (NCT05574439)
- Testing
- TCOC treatment, Semaglutide 3 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Diabetes, Healthy
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.
- Trial name
- NCT02064348
- Testing
- semaglutide, moxifloxacin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Normal Weight, Overweight and Obesity
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design.
- Conditions
- Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
- Trial name
- NCT06487832
- Testing
- Subcutaneous GLP1-RA
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy…
- Trial name
- NCT02243098
- Testing
- semaglutide, digoxin, atorvastatin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteer Study, HPA
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.
- Conditions
- Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency
- Trial name
- PIANO (NCT06608433)
- Testing
- semaglutide
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland